Study Explores Blood Markers for Alzheimer's Amyloid Clearance

A longitudinal study in The Lancet Neurology suggests specific blood proteins could help track amyloid clearance and provide prognostic data for early Alzheimer's patients on lecanemab. Researchers observed changes in 34 plasma proteins, with some nearing levels found in individuals without amyloid buildup. Further validation in larger, diverse groups is needed before these blood tests can replace current monitoring methods like PET imaging.